HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Futura Gains EU CE Mark For Drug-Free OTC Erectile Dysfunction Treatment

Executive Summary

Futura Medical has received a CE Mark for its MED3000 erectile dysfunction treatment, which combines in gel form a mixture of volatile and non-volatile ingredients.

You may also be interested in...

Futura Takes Drug-Free Erectile Dysfunction Gel To Latin America

UK based Futura Medical has struck a deal with m8 Pharmaceuticals to take its drug-free erectile dysfunction gel to Brazil and Mexico.

Futura’s Drug-Free Erectile Dysfunction Gel On Track For US And EU Launch

Futura Medical's latest meeting with the FDA puts the UK start-up one step closer to launching its drug-free erectile dysfunction gel MED3000 in the US in 2023, while the firm gets ready to launch in the EU next year following its recent CE-mark approval. 

'The Best Game In Town': Futura’s Skin-Based CBD Delivery System Shows Great Promise

UK R&D company Futura Medical's new CBD gel shows great potential as an effective cosmetic or even as a new kind of anti-inflammatory medicinal product.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts